This is a promotional website intended for UK healthcare professionals.
Colobreathe® (colistimethate sodium) Prescribing Information can be found here.
Adverse Event Reporting Information can be found at the end of this page.
This is a promotional website intended for UK healthcare professionals.
Colobreathe® (colistimethate sodium) Prescribing Information can be found here.
Adverse Event Reporting Information can be found at the end of this page.
Colobreathe® Administration Video
This video has been developed by Essential Pharma for patients who have been prescribed Colobreathe® by their healthcare team. It provides step-by-step instructions on how to use the Turbospin® inhaler, including guidance on administration, cleaning, storage, disposal, and how to report side effects. The video is also available to patients via the Colobreathe.co.uk patient site.
Colobreathe® Instructional Guide
This guide provides patients and caregivers with step-by-step instructions on how to use Colobreathe® and the Turbospin® inhaler effectively, including information on dosage, administration, cleaning and storage.
Colobreathe® Leave Piece
This promotional material provides healthcare professionals with a detailed overview of Colobreathe®, including its clinical efficacy, safety profile, and practical benefits for cystic fibrosis management.
CF, Cystic Fibrosis.
References:
1. Schuster A, Haliburn C, Döring G, et al. Thorax 2013;68:344–350.
2. Colobreathe® Summary of Product Characteristics. Available here.
Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk or search for the MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Essential Pharma on +44 (0) 1423 850700 or at EssentialpharmaUK@EU.ProPharmaGroup.com.
Essential Pharma Ltd, 8A Crabtree Road, Egham, Surrey, TW20 8RN, United Kingdom
Colobreathe® is a registered trademark of Essential Pharma. Copyright © 2026 Essential Pharma
MAT-COL-GB-0002-0625 June 2025
